Sign In
Buy GH
$127.03
-3.14 (-2.41%)
At Close: Jun 03, 2026
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
08:01pm, Thursday, 22'nd Feb 2024
The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
07:21pm, Thursday, 22'nd Feb 2024
Guardant Health (GH) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.36 per share a year ago.
Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet
10:56am, Thursday, 22'nd Feb 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 109.9% in Guardant Health (GH). While the effectiveness of this highly sought-after metric is questionable, the
Guardant Health to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 15'th Feb 2024
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. Citi 2
Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Thursday, 15'th Feb 2024
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down -12.91% in 4 Weeks, Here's Why Guardant Health (GH) Looks Ripe for a Turnaround
10:36am, Friday, 02'nd Feb 2024
Guardant Health (GH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estim
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
04:05pm, Thursday, 01'st Feb 2024
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2023
3 Stocks to Buy for the Age of Personalized Medicine
09:25am, Sunday, 28'th Jan 2024
I'm bullish on the long-term trajectory of personalized medicine stocks. These companies specialize in tailoring a holistic approach to healthcare, with medical treatments tailored to the individual c
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
08:05am, Wednesday, 17'th Jan 2024
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present interim data from the COSMOS study supporting the use of Guardant Reveal to p
7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024
02:48pm, Monday, 08'th Jan 2024
2023 was dominated by the Magnificent Seven stocks, which has left investors wondering how much higher mega-cap stocks can go. Investors worry that growth is nearing a peak or perhaps reversing.
Guardant Health shares slide as colon cancer test is set for FDA advisory committee review
08:42am, Wednesday, 20'th Dec 2023
Shares of Guardant Health Inc. GH, +2.50% dropped 9.5% premarket on Wednesday after the company said late Tuesday that a U.S. Food and Drug Administration advisory committee will review its colorectal
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present data showing the utility of liquid biopsy tests in the management of breast c
Guardant Health, Inc. (GH) Q3 2023 Earnings Call Transcript
08:53pm, Monday, 06'th Nov 2023
Guardant Health, Inc. (NASDAQ:GH ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy - Co-CEO AmirAli Talasaz - Co-CEO Michael Bell
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
04:05pm, Monday, 16'th Oct 2023
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will report financial results for the third quarter of 2023 af
1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years
09:53am, Wednesday, 11'th Oct 2023
Guardant Health's various products are all designed to help physicians and patients fight cancer. The company's revenue growth has been good, but its net losses are helping drag down the stock.
